Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155192 | 0.91 | REN (0.59) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL24155357 | 0.91 | REN (0.59) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL24155486 | 0.91 | ACE (0.59) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL24155266 | 0.86 | REN (0.53) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL24155190 | 0.85 | REN (0.58) | REN | |
| SCHEMBL24155272 | 0.85 | KLK5 (0.59) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL29602242 | 0.81 | KMT2A (0.67) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL8130179 | 0.81 | KMT2A (0.67) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL22961954 | 0.81 | CTSS (0.55) | CTSSCTSLCTSBCTSKREN | |
| SCHEMBL21219305 | 0.81 | ACE (0.72) | CTSSCTSLCTSBCTSKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403505-A1 | PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403505-A1 | PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS | OPRK1, OPRL1, OPRM1 | CTSS 1673/4885CTSL 1164/4885CTSB 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.